Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Trial Profile

Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Temozolomide (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 19 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top